A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3081-3087

  Alvarez, Ronald D ^a,d   Barnes, Mack N ^a   Gomez Navarro, Jesus ^b   Wang, Minghui ^b   Strong, Theresa V ^b   Arafat, Waleed ^b   Arani, Ramin B ^a   Johnson, Martin R ^c   Roberts, Bruce L ^a   Siegal, Gene P ^a   Curiel, David T ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c The Purdue Univ Univ of Alabama at Birmingham Botanical Center for Age Related Disease   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ONCOPROTEIN; VIRUS ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC CODE; HUMAN; HUMORAL IMMUNITY; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOVIRUSES, HUMAN; AGED; ANTIBODIES, NEOPLASM; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, ERBB-2; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 18544408628     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Barnes, M. N., Deshane, J. S., Rosenfield, M., Siegal, G. P., Curiel, D. T., and Alvarez, R. D. Gene therapy and ovarian cancer: a review. Obstet. Gynecol., 89: 145-155, 1997.
2. Gomez-Navarro, J., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Gene therapy: ovarian carcinoma as the paradigm. Am. J. Clin. Pathol., 109: 444-467, 1998.
3. Wels, W., Moritz, D., Schmidt, M., Jeschke, M., Hynes, N. E., and Groner, B. Biotechnological and gene therapeutic strategies in cancer treatment. Gene, 159: 73-80, 1995.
4. Jones, S. D., and Marasco, W. A. Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Adv. Drug Delivery Rev., 31: 153-170, 1998.
5. Pelegrin, M., Marin, M., Noel, D., and Piechaczyk, M. Genetically engineered antibodies in gene transfer and gene therapy. Hum. Gene Ther., 9: 2165-2175, 1998.
6. Beerli, R. R., Wels, W., and Hynes, N. E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem., 269: 23931-23936, 1994.
7. Hudziak, R. M., Schlessinger, J., and Ulrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
8. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54: 105-115, 1988.
9. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
10. Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., and Curiel, D. T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective antiproliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther., 1: 332-337, 1994.
11. Deshane, J., Siegal, G. P., Alvarez, R. D., Wang, M., Feng, M., Cabrera, G., Kay, M., and Curiel, D. T. Targeted tumor cell killing via an intracellular antibody against erbB-2. J. Clin. Invest., 96: 2980-2989, 1995.
12. Deshane, J., Cabrera, G., Grim, J. E., Siegal, G. P., Pike, J., Alvarez, R. D., and Curiel, D. T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol. Oncol., 59: 8-14, 1995.
13. Deshane, J., Grim, J., Loechel, S., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Intracellular antibody directed against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther., 3: 89-98, 1996.
14. Deshane, J., Siegal, G. P., Wang, M., Wright, M., Bucy, R. P., Alvarez, R. D., and Curiel, D. T. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol. Oncol., 64: 378-385, 1997.
15. Grim, J., Deshane, J., Feng, M., Lieber, A., Kay, M., and Curiel, D. T. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells. Am. J. Respir. Cell Mol. Biol., 15: 348-354, 1996.
16. Alvarez, R. D., and Curiel, D. T. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther., 8: 229-242, 1997.
17. Marasco, W. A., Chen, S., Richardson, J. H., Ramstedt, U., and Jones, S. D. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum. Gene Ther., 20: 9: 1627-1642, 1998.
18. Tait, D. L., Obermiller, P. S., Redlin-Frazier, S., Jensen, R. A., Welcsh, P., Dann, J., King, M., Johnson, D. H., and Holt, J. T. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin. Cancer Res., 3: 1959-1968, 1997.
19. Link, C. J., Eldeman, M., Tennant, L., Levy, J., Moorman, D. W., and Seregina, T. LTKOSN.1 murine vector producer cell (VPC) for the in vivo delivery of the herpes simplex thymidine kinase (HSVtk) gene for ovarian cancer (Abstract). Am. Soc. Gene Ther., 1999.
20. Knowles, M. R., Hohneker, K. W., Zhou, Z., Olsen, J. C., Noah, T. L., Hu, P. C., Leigh, M. W., Engelhardt, J. F., Edwards, L. J., Jones, K. R., Grossman, M., Wilson, J. M., Johnson, L. G., and Boucher, R. C. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med., 333: 823-831, 1995.
21. Porteous, D. J., Dorin, J. R., McLachlan, G., Davidson-Smith, H., Davidson, H., Stevenson, B. J., Carothers, A. D., Wallace, W. A., Moralee, S., Hoenes, C., Kallmeyer, G., Michaelis, U., Naujoks, K., Ho, L. P., Samways, J. M., Imrie, M., Greening, A. P., and Innes, J. A. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther., 4: 210-218, 1997.
22. Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M., and Kaiser, L. R. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther., 9: 1083-1092, 1998.
23. Harvey, B. G., Hackett, N. R., El Sawy, T., Rosengart, T. K., Hirschowitz, E. A., Lieberman, M. D., Lesser, M. L., and Crystal, R. G. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol., 73: 6729-6742, 1999.
24. Nunes, F. A., Furth, E. E., Wilson, J. M., and Raper, S. E. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum. Gene Ther., 10: 2515-2526, 1999.
25. Ueno, N. T., Hung, M. C., Weiden, P., Wolf, J. K., Xia, W., Zhang, S., Daifuku, R., Kilbourn, R. G., Willey, J. S., Warner, D. L., Payne, J. Y., Nandagiri, R., Aldridge, R., Carey, M., Lincoln, S. T., Aboulafia, D., De Jager, R. L., Tucker, S., Putnam, J. B., Sneige, N., Katz, R. L., Spohn, W. H., Bast, R. C., Holmes, F. A., Ibrahim, N. K., Murray, J. L., Theriault, R. L., Rahman, Z. U., Valero, V., Kudelka, A. P., Kavanagh., J., Freedman, R. S., Gerhenson, D. M., Bevers, M. W., Huang, L., Lopez-Berestein, L. G., and Hortobagyi, G. N. Phase I trial of E1A gene therapy in patients with advanced breast and ovarian cancers (Abstract). Am. Soc. Gene Ther., 1998.
26. Buller, R. E., Pegrum, M., Runnebaum, I., et al. A phase I study of gene therapy with recombinant intraperitoneal p53 in recurrent ovarian cancer. Cancer Gene Ther., 5: S25, 1998.
27. Buller, R. E., Pegram, M., Runnebaum, I., Horowitz, J. A., Buekers, T. E., Salko, T. P., Rybak, M. E., Shahin, M. S., Kreienberg, R., Karlan, B., and Slamon, D. A phase I/II trial of recombinant adenoviral human p53 (SCH58500) intraperitoneal (ip) gene therapy in recurent ovarian cancer. Gynecol. Oncol., 72: 452, 1999.
28. Rogers, B. E., McLean, S. F., Kirkman, R. L., Della Manna, D., Bright, S. J., Olsen, C. C., Myracle, A. D., Mayo, M. S., Curiel, D. T., and Buchsbaumm D. J. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin. Cancer Res., 5: 383-393, 1999.
29. Gomez-Navarro, J., Curiel, D. T., and Douglas, J. T. Gene therapy for cancer. Eur. J. Cancer, 35: 867-885, 1999.
30. Khuu, H., Conner, M., Vanderkwaark, T., Shultz, J., Gomez-Navarro, J., Alvarez, R. D., Curiel, D. T., and Siegal, G. P. Detection of Coxsackie-adenovirus receptor (CAR) immunoreactivity in ovarian tumors of epithelial derivation. Appl. Immunohistochem. Mol. Morphol., 7: 266-270, 1999.
31. Vanderkwaak, T. J., Wang, M., Gomez-Navarro, J., Rancourt, C., Dmitriev, I., Krasnykh, V., Barnes, M., Siegal, G. P., Alvarez, R., and Curiel, D. T. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol., 74: 227-234, 1999.
32. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
33. Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., and Roth, J. A. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res., 58: 2288-2292, 1998.
34. Dilber, M. S., Phelan, A., Aints, A., Mohamed, A. J., Elliott, G., Edvard Smith, C. I., and O'Hare, P. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther., 6: 12-21, 1999.